Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESR-114 in plaque psoriasis
NCT03630939Phase 2Completed
- Sponsor
- Escalier Biosciences
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ESR-114 in plaque psoriasis (3 arms), sponsored by Escalier Biosciences. Primary endpoint: Change in Total Lesion Severity Score at 6 weeks. Started Aug 2018; status: completed.
02
Drugs
ESR-114
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03630939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630939.